Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Overview
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Companies Involved in Therapeutics Development
Aevitas Therapeutics Inc
Alexion Pharmaceuticals Inc
ChemoCentryx Inc
Chugai Pharmaceutical Co Ltd
Immubs Inc
ISU ABXIS Co Ltd
Novartis AG
Omeros Corp
Prestige BioPharma Ltd
Ra Pharmaceuticals Inc
Samsung Bioepis Co Ltd
Tasly Biopharmaceuticals Co Ltd
Turgut Ilaclari AS
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Drug Profiles
avacopan - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVTS-001 - Drug Profile
Product Description
Mechanism Of Action
B-20672 - Drug Profile
Product Description
Mechanism Of Action
CPV-101 - Drug Profile
Product Description
Mechanism Of Action
CPV-102 - Drug Profile
Product Description
Mechanism Of Action
crovalimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
danicopan - Drug Profile
Product Description
Mechanism Of Action
History of Events
eculizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
eculizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
eculizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
IM-101 - Drug Profile
Product Description
Mechanism Of Action
iptacopan hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclol Antibody for Atypical Hemolytic Uremic Syndrome and Paroxysmal Nocturl Hemoglobinuria - Drug Profile
Product Description
Mechanism Of Action
History of Events
rsoplimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
ravulizumab LA - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit MASP2 for Immunology - Drug Profile
Product Description
Mechanism Of Action
zilucoplan - Drug Profile
Product Description
Mechanism Of Action
History of Events
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Dormant Projects
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Discontinued Products
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Product Development Milestones
Featured News & Press Releases
Sep 14, 2021: Eleva reaches industrial production scale and prepares for clinical development of Factor H
May 10, 2021: The Scottish Medicines Consortium accepted Ultomiris for routine use
Mar 16, 2021: vigo Proteins and Eleva announce successful development of an affinity chromatography resin customized for the efficient purification of human complement-factor H
Jan 06, 2021: Eleva secures up to EUR 60 million to advance a drug candidate, appoints new Board Member
Nov 24, 2020: ISU ABXIS and Russian Pharmasyntez signed ISU305 technology export contract
Nov 04, 2020: Alexion announces upcoming data presentations at the 62nd American Society of Hematology Annual Meeting and Exposition
Oct 12, 2020: Alexion receives FDA approval for new advanced formulation of ULTOMIRIS (ravulizumab-cwvz) with significantly reduced infusion time
Oct 09, 2020: Alexion announces upcoming data presentations at the American Society of Nephrology’s Virtual Kidney Week 2020
Sep 25, 2020: ULTOMIRIS (ravulizumab) receives approval in Japan for atypical hemolytic uremic syndrome (aHUS) in adults and children
Jun 29, 2020: ULTOMIRIS (ravulizumab) receives marketing authorization from European Commission for adults and children with atypical hemolytic uremic syndrome (aHUS)
Jun 24, 2020: Alexion announces phase 3 study of weekly subcutaneous ULTOMIRIS (ravulizumab-cwvz) met primary endpoint
May 14, 2020: Alexion announces upcoming data presentations at the virtual 25th Congress of the European Hematology Association
Oct 18, 2019: Alexion receives FDA approval for ULTOMIRIS (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (aHUS)
Jun 20, 2019: U.S. FDA accepts Supplemental Biologics License Application (sBLA) for ULTOMIRIS (ravulizumab-cwvz) under priority review for the treatment of atypical hemolytic uremic syndrome (aHUS)
Jan 28, 2019: Alexion announces positive top-line results from phase 3 study Of ULTOMIRIS (Ravulizumab-Cwvz) in complement inhibitor-ive patients with Atypical Hemolytic Uremic Syndrome (AHUS)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Aevitas Therapeutics Inc, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by ChemoCentryx Inc, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by ImmunAbs Inc, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by ISU ABXIS Co Ltd, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Novartis AG, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Omeros Corp, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Prestige BioPharma Ltd, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Ra Pharmaceuticals Inc, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Samsung Bioepis Co Ltd, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Tasly Biopharmaceuticals Co Ltd, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Turgut Ilaclari AS, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Dormant Projects, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Discontinued Products, 2022